News

Proteomic study published in Nature paves the way for new treatment for incurable leukaemia using an epigenetic inhibitor

03 October 2011

A study published in Nature online today (Dawson et al. Advanced online Publication, DOI: 10.1038/nature10509) by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.

A study published in Nature online today (Dawson et al. Advanced online Publication, DOI: 10.1038/nature10509) by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.

Commenting on the results, Dr David Simmons, CSO of Cellzome said: “This publication shows how our chemoproteomic technology can guide epigenetic drug discovery. This new and exciting field of biology offers great potential for developing novel therapeutic interventions as ‘personalised epigenetic medicines’, and I am pleased that the expertise we have built at Cellzome is making a significant contribution at the forefront of this field.”

Members' Login

Our website uses cookies. Cookies enable us to provide the best experience possible and help us understand how customers
use our website.Our site won't work without them. By continuing to use our website you accept our use of cookies.
Find out more about cookies×